{
    "authors": [
        {
            "affiliations": [],
            "name": "Wentao YU"
        },
        {
            "affiliations": [],
            "name": "Man LUO"
        },
        {
            "affiliations": [],
            "name": "Huan WU"
        },
        {
            "affiliations": [],
            "name": "Yayun YU"
        },
        {
            "affiliations": [],
            "name": "Junmao LI"
        },
        {
            "affiliations": [],
            "name": "Minzhen HE"
        },
        {
            "affiliations": [],
            "name": "Yunlin FENG"
        },
        {
            "affiliations": [],
            "name": "Shilin YANG"
        },
        {
            "affiliations": [],
            "name": "Wugang ZHANG"
        },
        {
            "affiliations": [],
            "name": "Min YAO"
        }
    ],
    "id": "SP:e45557f0891a3a63ee23623c8a6298c2efc62f25",
    "references": [
        {
            "authors": [
                "anti-inflammatory Carvalho"
            ],
            "title": "Hexahydrofarnesyl acetone",
            "year": 2020
        },
        {
            "authors": [
                "Ansari"
            ],
            "title": "The differential non-volatile components",
            "year": 2016
        },
        {
            "authors": [
                "hepyrotection Usmanov"
            ],
            "title": "Forsythoside B phenylpropanoid glycosides",
            "year": 2021
        }
    ],
    "sections": [
        {
            "text": "The Tibetan medicine \u2018LuRu\u2019 have a wide range of ethnopharmacological uses.\nThe common \u2018LuRu\u2019 varieties are P. flava and P. muscicola. The volatile components\nwere qualitative and semi-quantitative analysis by GC-MS. A total of 46 compounds from volatile components of P. flava and P. muscicola were identified. The\ncompounds mainly contain terpenoids, fatty acids, alkanes and other compounds. The non-volatile components were qualitative and semi-quantitative analysis by UHPLC-\nQ-TOF-MS. A total of 68 compounds were identified from non-volatile components of P. flava and P. muscicola. The compounds mainly contain iridoids, flavonoids,\nlignans, phenylpropanoid glycosides, organic acids, alkaloids and other compounds. Both\u2018LuRu\u2019 stemed from P. flava or P. muscicola are significant differences in volatile and non-volatile components, so the two herbs can\u2019t be mixed or substituted in clinical medication. The P. flava can represent the efficacy of Tibetan medicine\n\u2018LuRu\u2019. 1. Experimental 1.1 Materials and chemicals\nP. flava and P. muscicola were come from Lhasa, Tibet, China. The P. flava were\ncollected on 19 May 2020 and the P. muscicola on 18 March 2020, respectively. P. flava and P. muscicola were identified to The Jiangxi University of Chinese Medicine\nresource identification expert Guoyue ZHONG. The specimens P. flava (NO.20210519) and P. muscicola (NO.20210318) were deposited in the National\nEngineering Research Center for Manufacturing Technology of solid preparations of Chinese Jiangxi University of Chinese Medicine. The reference standards of cinnamic\nacid, loganic acid, homogentisic acid, acteoside, luteolin, and quercetin were purchased from were purchased from National Institutes for Food and Drug Control\n(Beijing, China). Methanol and acetonitrile of HPLC grade were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Formic acid of HPLC grade was obtained\nfrom SIGMA Aldrich (St. Louis, USA). Distilled Water (A.S. Watson Group). All\nother chemicals and reagents were of HPLC grade. GraphPad Prism 8. 1.2 Preparation of samples 1.2.1 Sample preparation for volatile component analysis\nThe volatile components of P. flava or P. muscicola were extracted by steam\ndistillation in duplicates for 6 h (300 g in 3 L tap water). Cyclohexane was dissolved\nin essential oil (EO), then the volatile oil was collected in a graduated tube, dried over anhydrous sodium sulphate, and stored at 4 \u00b0C for further use.\n1.2.2 Sample preparation for non-volatile component analysis\nPrecisely weigh 1g of P. flava (or P. muscicola) powder, put it in a 50 ml conical\nflask, add 10 ml of methanol, weigh and ultrasonicate for 30 min, take it out and let it cool, weigh it, make up for the loss with methanol, shake well, and filter it through a\n0.22 \u03bcm microporous filter. Membrane filtration, take the continuous filtrate. 1.3 GC\u2013MS analysis condition\nGC-MS analysis was performed to characterise the volatile composition of P.\nflava and P. muscicola. Agilent benchtop GC-MS (Agilent Technologies, Wilmington, DE, USA) equipment with a capillary column of HP-5MS (60 m length, 0.25 mm i.d.,\n0.25 \u03bcm film thickness) was used for the test sample analysis. Argon was used as the carrier gas at a flow rate of 1 mL/min. The oven temperature was programmed as\nfollows: 50 \u00b0C for 3 min, 130 \u00b0C at 5 \u00b0C/min, 200 \u00b0C at 10 \u00b0C/min, 200 \u00b0C for 2 min, 300 \u00b0C at 5 \u00b0C/min, and 300 \u00b0C for 10 min, resulting in a total run time of 58 min.\nThe injected sample volume was 1 \u03bcL with a split ratio of 10:1. GC-MS data were captured at 70 eV using scanning times of 1.5 sec in the mass range of 50\u2013550 m/z.\nFurther identification of essential oil constituents was performed by comparing the fragmentation patterns of mass spectra obtained by GC/MS analysis with those stored\nin the NIST17.L library and calculating the relative mass fraction of each component by peak area normalization. Relative percentage amounts of the separated compounds\nwere calculated from total ion chromatograms by the computerized integrator. 1.4 UPLC-Q-TOF-MS analysis condition\nUPLC-Q-TOF-MS analysis was performed to characterise the non-volatile\ncomposition of P. flava and P. muscicola. Liquid chromatographic analysis was performed using Nexera UPLC LC-30A instrument. The sample was separated on\nWelch Ultimate\u00ae UHPLC XB-C18 (3\u00d7100 mm, 1.8 \u03bcm) at 40 \u00b0C. The mobile phase consisted of water, 0.1 % formic acid (A), and acetonitrile (B). A gradient elution was\nprogrammed as follows: 0.01\u20135 min, 5\u20138 % B; 5\u201312 min, 8\u201312 % B; 12\u201330 min, 12\u2013 20 % B; 30\u201335 min, 20\u201335 % B, 35\u201338 min, 35\u201350 % B; 38\u201340 min, and 50\u201395 % B.\nThe flow rate and the injection volume were set at 0.3 mL/min and 3 uL, respectively.\nThe UPLC system was coupled to a Triple TOF TM 5600 (AB SCIEX, Foster\nCity, Canada) equipped with an electrospray ionisation (ESI) source. Q-TOF-MS analysis was performed in both positive and negative ion modes in the full scan mode.\nThe optimised MS parameters were set as follows: ion spray voltage (ISV): 5500 V (ESI+) or \u22124500 V (ESI\u2212); ion source temperature (TEM): 550 \u00b0C or 450 \u2103; ion\nsource gas 1 (GS1): 60 psi; ion source gas 2 (GS2): 50 psi; curtain gas (CUR): 40 psi; declustering potential (DP): 100 V; collision energy (CE): 40/\u221240 eV (MS mode);\ncollision energy spread (CES): 15 eV; scan range of TOF-MS; and product ion: m/z 50\u20131250 Da. Moreover, to ensure accurate mass measurements during the MS\nexperiments, the Triple TOFTM system was calibrated every 2 h in positive/negative mode using APCI-positive/negative calibration solutions supplied by AB SCIEX. All\ndata were collected and analysed using Analyst TF 1.6 (version 1.0; AB SCIEX, Foster City, CA), Peak View \u00ae 1.6 (AB SCIEX, Foster City, Canada), and Master\nView 1.0 softwares (AB SCIEX, Foster City, CA). Structures and fragmentation pathways were generated using Chemdraw 18.1 (Perkin-Elemer, USA).\nFigure S1: GC-MS Chromatograms of P. flava\nFigure S2: GC-MS Chromatograms of P. muscicola\nFigure S3: UPLC/Q-TOF-MS/MS total ion flow chart A (+) and B (-) of P. flava\nFigure S4: UPLC/Q-TOF-MS/MS total ion flow chart A (+) and B (-) of P. muscicola\nFig S5: The venny maps and heat maps of Pedicularis flava\nFig S6: The venny maps and heat maps of Pedicularis muscicola\nTable S1. Chemical composition of essential oil from P. flava and P. muscicola by GC-MS\nNO. RT Compounds Chemical Formula CAS Contents (%)\nF M\n1 4.14 Benzyl oleate C25H40O2 55130-16-0 nd 1.33 2 4.60 Carvone semicarbazone C11H17N3O 4581-65-1 nd 0.48 3 22.63 \u03b2-Ionone C13H20O 14901-07-6 0.28 nd 4 24.44 Cedrol C15H26O 77-53-2 0.27 nd 5 27.28 Neophytadiene C20H38 504-96-1 nd 0.27 6 27.41 Hexahydrofarnesyl acetone C18H36O 502-69-2 6.46 1.51 7 28.17 Hexadecane C16H34 544-76-3 0.43 nd 8 28.56 Farnesyl acetone C18H30O 1117-52-8 1.31 nd 9 28.60 13-methyl Pentadecanoic Acid methyl ester C17H34O2 5487-50-3 1.01 1.01\n10 28.61 Methyl palmitate C17H34O2 112-39-0 0.79 0.54 11 28.98 Myristic acid C14H28O2 544-63-8 0.45 nd 12 29.69 Stearic acid C18H36O2 57-11-4 0.24 nd 13 29.70 Ethyl palmitate C18H36O2 628-97-7 0.49 0.31 14 31.18 Methyl 3-bromo-1-adamantaneacetate C13H19BrO2 14575-01-0 0.67 nd 15 31.34 4-ethylbenzyl alcohol C9H12O 768-59-2 nd 0.73 16 31.37 (9Z,15Z)-9,15-Octadecadienoic acid methyl ester C19H34O2 17309-05-6 nd 1.02 17 31.39 12,15-Octadecadienoic acid, methyl ester C19H34O2 57156-97-5 0.50 nd 18 31.41 4-Methyltetradecane C15H32 25117-24-2 nd 0.77 19 31.43 8-Methylheptadecane C18H38 13287-23-5 0.71 nd 20 31.5 Palmitic acid C16H32O2 57-10-3 27.53 1.96 21 31.51 Methyl Linolenate C19H32O2 301-00-8 1.51 3.41 22 31.64 4-Hydroxypalmitic acid lactone C16H30O2 730-46-1 0.80 nd 23 31.75 Phytol C20H40O 150-86-7 7.19 5.85 24 31.76 Oleic acid C18H34O2 112-80-1 nd 4.83 25 32.22 Dehydroisophytol C20H38O 29171-23-1 0.80 nd 26 32.60 Ethyl linolenate C20H34O2 1191-41-9 nd 1.05 27 32.62 3-Methylheneicosane C22H46 6418-47-9 1.58 nd 28 32.63 3-Deoxyestradiol C18H24O 2529-64-8 2.05 nd 29 33.08 2,6,10-trimethyltridecane C16H34 3891-99-4 0.32 nd 30 34.71 Tricosane C23H48 638-67-5 5.46 6.15 31 35.69 l-ascorbyl dipalmitate C38H68O8 28474-90-0 0.26 2.22 32 35.87 2-Methyltetracosane C25H52 1560-78-7 0.74 0.58 33 36.29 Heneicosane C21H44 629-94-7 nd 2.05 34 36.30 Tetracosane C24H50 646-31-1 1.21 0.97 35 37.28 7-Hexyldocosane C28H58 55373-86-9 nd 2.94\n36 37.91 Pentacosane C25H52 629-99-2 9.02 19.46 37 39.34 Hexacosane C26H54 630-01-3 0.89 2.15 38 39.35 3-Ethyl-5-(2-ethylbutyl)-octadecane C26H54 55282-12-7 0.69 2.39 39 40.26 3-Methylpentacosane C26H54 6902-54-1 nd 0.78 40 40.27 2-Bromooctadecanal C18H35BrO 56599-95-2 0.28 nd 41 40.82 Heptacosane C27H56 593-49-7 5.62 10.04 42 41.84 3-Methylheptacosane C28H58 14167-66-9 nd 0.57 43 43.06 27-Methyloctacosane C29H60 1560-98-1 nd 0.30 44 43.56 Hentriacontane C31H64 630-04-6 5.41 6.30 45 43.57 Nonacosane C29H60 630-03-5 3.15 6.40 46 44.55 3-Methylnonacosane C30H62 14167-67-0 nd 0.28\nTerpenoids (NO. 3~6, 8, 23, 25) Fatty acids (NO. 11~13, 20, 24) Alkanes (NO. 7, 18, 19, 29, 30, 32~39, 41~46) Other (NO. 1, 2, 9, 10, 14~17, 21, 22, 26~28, 31, 40)\n16.31 7.63 28.71 7.10 33.65 62.13\n9.45 11.79\nSUM 88.12 88.65\nTable S2: Identification of the major compounds present in P. flava and P. muscicola by UPLC-Q-TOF-MS\nNO. tR/min Compound name Molecular\nFormula\nParent\nion\nExact Mass ppm Fragmentation Categories\nBelonging Species\n1 0.97 D-mannitol C6H14O6 [M-H]- 181.0715 1.1 181.0715,163.0615,113.0243,101.0253,89.0253,\n71.0156\nFM T\n2 1.11 6-(1'',3''-Dihydroxy-2''-\npropoxyl)- inosine\nC13H18N4O7 [M-H]- 341.1103 -2.2 341.1103,267.0688,221.0664,119.0357,113.0246,\n89.0253\nFM T\n3 1.59 Adenosine C10H13N5O4 [M+H]+ 268.1040 0.9 268.1040,136.0613,119.0350 M T 4 1.71 Iridolactone C9H12O4 [M-H]- 183.0662 -0.4 183.0662,165.0512,153.0522,147.0430,135.0422,\n121.0359,119.0466,107.0432,93.0427\nFM I\n5 2.14 Maltol-\u03b2-D-\nglucopyranoside\nC13H18O7 [M+Na]+ 309.0945 0.4 309.0945,287.1133 F T\n6 2.23 Tortoside C C26H32O13 [M-H]- 551.1812 1.6 551.1812,505.1948,389.1260,341.1020 F L 7 2.29 Aucubin C15H22O9 [M+H]+ 347.1313 -0.2 347.1313,287.1138,185.0804 FM I 8 2.30 Cinnamic acid* C9H8O2 [M+H]+ 149.0594 0.2 149.0594,121.0290,103.0520,91.0550,77.0392 FM O 9 2.97 N-methylcytisine C12H16N2O [M+H]+ 205.1357 2.3 205.1357,149.0249,134.0966,118.0636,93.0326,\n72.0448\nF A\n10 3.76 Pediculinine C10H13NO [M+H]+ 164.1070 1.4 164.1070,146.0955,131.0720,130.0642,103.0534,\n91.0536,77.0381\nFM A\n11 3.89 Sesamoside C17H24O12 [M-H]- 419.1138 3.1 373.1138,211.0605,146.9651,123.0448 F I 12 3.97 Lamalbid C17H26O12 [M-H]- 421.1429 -1.2 421.1429,375.1359,357.1249,297.1023,267.0910,\n213.0799,195.0690,177.0578\nM I\n13 4.04 2,5-Hydroxybenzoic acid C7H6O4 [M-H]- 153.0193 -3.2 153.0193,123.0433,109.0292,108.0212,91.0193 F O\n14 4.08 6-Methylcoumarin C10H8O2 [M+H]+ 161.0639 1.3 161.0639,133.0646,115.0547,103.0543,91.0541 M I 15 4.12 Trochocarposide C14H20O8 [M-H]- 315.1078 2.7 315.1078,178.9578,153.0546,90.9967,135.0444 FM P 16 4.23 Plantagonine C10H11NO2 [M+H]+ 178.0874 1.8 178.0874,162.0558,160.0770,144.0447,132.0816,\n118.0655,117.0573,91.0550\nFM A\n17 5.07 Gardoside C16H22O10 [M+H]+ 375.1317 1.2 375.1315,357.1239,297.1021,213.0793,195.0683,\n177.0576,149.0628\nFM I\n18 5.29 Loganic acid C16H24O10 [M-H]- 375.1305 1.9 375.1305,213.0761,195.0656,169.0868,151.0762,\n125.0607,107.0507,89.0252\nFM I\n19 5.65 2H-Quinolinone C9H7NO [M+H]+ 146.0618 1.7 146.0618,118.0628,91.0576,77.04 M A 20 5.71 Shanzhiside methyl ester C17H26O11 [M-H]- 405.1418 2.6 405.1418,359.1351,197.0810,153.0548 FM I 21 5.88 Pedicularioside F C22H34O15 [M-H]- 537.1864 0.5 537.1864,384.9413,316.9462,248.9592,112.9855 FM I 22 5.91 Salidroside C14H20O7 [M-H]- 299.1136 1.8 119.0504,89.0263,59.0158 FM P 23 6.12 Salicylic acid C7H6O3 [M-H]- 137.0242 -0.1 121.0278,77.0394,65.0403 FM O 24 7.53 Indicaine C10H11NO [M+H]+ 162.1278 3.2 162.1278,160.0761,147.1057,144.0429,132.0808,118\n.0635,117.0571\nM A\n25 7.69 Argyol C9H12O3 [M+H]+ 169.0859 1.1 151.0785,123.0439,105.0345,95.0863,79.0545 F I 26 8.54 Homogentisic acid* C8H8O4 [M+H]+ 169.0495 2.0 169.0495,151.0354,123.0414,110.0351,93.0332,77.0\n399,65.0394\nFM O\n27 12.57 Longiflorosides B C26H32O11 [M-H]- 521.2017 0.7 357.1342,342.1133,314.9328,178.9578,136.0170 M L 28 12.70 8-epi-Loganin C17H26O10 [M+H]+ 391.1694 0.1 391.1694,391.1542,149.0232 FM I 29 13.14 Gardoside methyl ester C17H24O10 [M-H]- 387.1304 1.1 387.1304,341.1261,251.0905,179.0709,135.0458 M I 30 13.33 Kansuenin C14H22O4 [M+H]+ 255.1591 1.2 195.1378,149.1343,109.1035,93.0700 F I 31 15.57 Artselaeroside A C19H28O10 [M-H]- 415.1600 -0.2 415.1600,369.3512,347.1711,207.0993 FM P\n32 16.69 Deoxyloganic acid C16H24O9 [M-H]- 359.1359 5.0 359.1359,197.0181,153.0921,135.0815 FM I 33 16.77 Kansuenoside C16H24O8 [M-H]- 343.1435 3.8 343.1435,223.0996,181.0870 F I 34 16.78 Pedicularislactone C10H14O3 [M-H]- 181.0860 2.3 181.0860,137.0614,110.0614,71.0157 F I 35 16.93 Tortoside F C27H32O12 [M+H]+ 549.1987 0.9 549.1987,387.1434 FM L 36 16.95 beta-Indolylaldehyde C9H7NO [M-H]- 144.0469 1.6 144.0469,142.0318,126.0397,115.044 M A 37 17.90 Pedicularislactone C11H16O3 [M+H]+ 197.1172 4.4 179.1052,135.1186,133.1029,107.0865,105.0699,\n91.055\nFM I\n38 18.16 Longiflorosides C C27H36O13 [M-H] - 565.2057 2.4 521.2057,491.1974,359.1510,329.1401 F L 39 18.61 6-O-Butyl-aucubin C19H30O9 [M-H]- 401.1868 0.4 401.1868,399.9251,221.1218,195.1411,177.1306,\n161.0477\nM I\n40 19.34 Mussaenin A C10H16O4 [M-H]- 199.0975 2.1 181.0902,155.1077,137.0990 M I 41 20.16 Armaoside C27H34O13 [M-H]- 565.1957 3.2 565.1957,505.1748,403.1288,357.1346,339.1243,\n327.1242,312.1001,297.0772,207.0492,190.0635\nFM L\n42 20.96 Luteolin-7-O-glucuroside C21H18O12 [M-H]- 461.0749 3.6 461.0749,285.0415 FM F 43 21.32 Luteolin-4'-O-glucoside C21H20O11 [M-H]- 447.0953 4.2 447.0953,285.0406,284.0324 FM F 44 21.56 Forsythoside B C34H44O19 [M-H]- 755.2488 2.8 755.2488,593.2135,161.0240 F P 45 21.20 Verticillatoside A C26H32O12 [M-H]- 535.1824 3.6 535.1824,373.1283,329.1403 M L 46 22.63 (E)-2-exenyl \u03b2-\nsophoroside\nC12H22O6 [M-H]- 261.1355 -1.1 261.1355,187.0964,169.0859,143.1082,125.0970 F T\n47 23.14 Acteoside* C29H36O15 [M+H]+ 625.2049 1.1 623.2049,461.1701,315.1102,179.0357,161.0251 FM P 48 24.33 7-O-\nAcetylgardosidemethyl ester\nC19H26O11 [M+H]+ 431.2201 4.9 431.2201,183.1051,158.9650 F I\n49 25.85 Tortoside A C28H36O13 [M-H]- 579.2083 3.0 579.2083,417.1578,402.1342,387.1095,205.0862,\n181.0499,166.0258\nF L\n50 26.40 Dihydrocatalpolgenin C12H20O5 [M-H]- 243.1210 2.1 243.1210,225.1116,207.1018,181.1234,163.1128 FM I 51 28.08 Tricin-7-O-glucuronside C23H22O13 [M-H]- 505.1015 0.7 505.1015,329.0669,314.0432,271.0244,113.0242 FM F 52 28.62 cis-Tanoside C C30H38O15 [M+H]+ 639.2284 2.3 639.2284,461.1687,443.1577,193.0503,175.0397,\n160.0161,135.0449\nFM P\n53 31.90 Pedicularioside H C36H48O19 [M-H]- 783.2813 1.9 783.2813,607.2296,589.2180,193.0497,175.0394,\n160.0161\nF P\n54 33.40 Quercetin C15H10O7 [M-H]- 301.0365 1.6 301.0365,273.0411,245.0460,178.9987,151.0041,\n107.0146\nFM F\n55 33.64 Tortoside B C28H38O13 [M+H]+ 583.2852 0.6 583.2852,421.1834,377.1920 F L 56 33.65 Luteolin* C15H10O6 [M-H]- 285.0409 3.9 285.0409,257.0454,241.0505,217.0505,199.0398,\n175.0399,151.0035,133.0297,132.0215,107.0138\nFM F\n57 33.81 Dehydrodiconiferyl\nalcohol -4-O-\u03b2-Dglucoside\nC25H30O11 [M+H]+ 507.1877 4.1 507.1877,489.1738,339.1068,177.0545,145.0282 FM L\n58 33.82 Martynoside C31H40O15 [M-H]- 651.2363 2.8 651.2363,475.1855,378.9205,242.9438,193.0507,\n175.0395,134.0392\nF P\n59 34.24 Homoeriodictyol C16H12O7 [M-H]- 315.0518 4.2 315.0518,300.0282,272.0328,271.0248,243.0298 FM F 60 35.96 Pliatoside A C10H14O2 [M+H]+ 167.1078 2.1 167.1078,131.0866,105.0685,93.0702 FM I 61 36.00 Apigenin C15H10O5 [M-H]- 269.0453 2.8 269.0453,151.0033,149.0241,117.0350,107.142 FM F 62 36.55 Chrysoeriol C16H12O6 [M-H]- 299.0572 4.6 299.0572,284.0336,256.0380 FM F 63 36.61 Tricin C17H14O7 [M-H]- 329.0681 2.4 329.0681,314.0443,299.0203,271.0251,227.0348, FM F\n161.0242\n64 36.94 Boschnaloside C16H24O8 [M-H]- 343.2183 1.5 343.2183,227.1307,206.8981,183.1402,163.1306 M I 65 37.02 Tortoside E C27H36O12 [M+H]+ 553.2258 4.3 553.2258,535.2186,373.1505,355.1393 F L 66 37.17 Cirtusin A C26H34O11 [M+H]+ 523.2174 4.0 523.2174,359.1511,329.1420,316.9501 F L 67 37.87 Sissotrin C22H22O10 [M+H]+ 447.3398 2.7 447.3398,429.1197,385.0940,341.0674,297.0384,\n237.0769,193.0505,149.0237\nFM F\n68 38.34 Dehydrovomifoliol C13H18O3 [M+H]+ 223.1329 2.6 191.0000,149.0216 FM T\n1. *: Reference standards 2. F: Pedicularis flava; M: Pedicularis muscicola; FM: Pedicularis flava and Pedicularis muscicola 3. I: iridoids; F: flavonoids; P: phenylpropanoid glycosides; L: lignins; O: organic acids; A: alkaloids; T: other\nTable S3\uff1aList of active ingredients of P. flava and P. muscicola\nCompound Category Models Stimulus Target Pathway Effect Reference\nThe same volatile activity components Phytol terpenes Swiss mice CFA MPO\u2193, TNF-\u03b1\u2193, IL-6\u2193, COX-2\u2193 p38MAPK, NF\u03baB\nanti-inflammatory Carvalho et al.\n2020\nHexahydrofarnesyl acetone\nWistar mice Carrageenan TNF-\u03b1\u2193, COX-2\u2193, NOs2\u2193, PGE-\n2\u2193\nNF\u03baB, MAPK anti-inflammatory Avoseh et al.\n2021\nPalmitic acid long chain fatty\nacid\nHuman prostate cancer cells\nD1\u2193, p-Rb\u2193, p27\u2191, PKC\u03b6\u2193, pIntegrin\u03b21\u2193, E-cadherin\u2191, block prostate cancer proliferation and metastasis PI3K/Akt anti-cancer Zhu et al. 2021\nMethyl palmitate other Kupffer cells\nand Raw cells\nLPS TNF-\u03b1\u2193, IL-6\u2193, IL-10\u2193, NOs2\u2193 NF-\u03baB, p65\nMAPK\nanti-inflammatory and antifibrotic\nEl-Demerdash E. 2009\nThe same non-volatile components Shanzhiside methyl ester\niridoids Wistar mice lidocaine p38 MAPK anti-inflammatory Fan et al. 2016\nLoganic acid Wistar mice Streptozotocin GSH\u2193, MCH\u2193,OMP\u2193,\nCAT\u2191, GPx\u2191, GR\u2191\nPPAR\u03b1, PPAR\u03b3\nantioxidant Dzydzan et al.\n2020\nAucubin C57BL/6\nmice\nTyloxapol TC\u2193,TG\u2193,LDL\u2193,VLDL\n\u2193,MPO\u2193,SOD\u2193, TNF-\u03b1\u2193, IL-1\u03b2\u2193, IL-6\u2193\nNrf2/HO-1, AMPK\nanti-inflammatory and antioxidant\nshen et al. 2019\nCinnamic acid Wistar mice Ascites tumor\ncells\nBax/Bcl-2\u2193, caspase-3\u2193 PI3K/AKT anti-tumor and\nantioxidant\nAlmeer et al. 2019\nGardoside RAW 264.7 LPS NO\u2193,TNF -\u03b1\u2193,IL-6\u2193,IL-1 \u03b2\u2193 PI3K-Akt anti-inflammatory Ji et al. 2021 Deoxyloganic acid Human\nmelanoma cell\nAnti-proliferation anti-tumor Garro et al. 2021\nLuteolin-7-Oglucuroside\nflavonoids RAW 264.7 LPS NO\u2193, COX-2\u2193, IL-6\u2193, IL-1\u03b2\n\u2193, TNF-\u03b1\u2193, HO-1\u2191, GCLC \u2191, NAD(P)H \u2191, NQO1\u2191\nNF-\u03baB, Nrf2 anti-inflammatory\nand antioxidant\nCho et al. 2020\nQuercetin BALB/c\nmice\nLNCaP Bax/Bcl-2\u2193, caspase-3\u2193 PI3K/AKT anti-tumor Yang et al. 2015\nApigenin Kunming\nmice\nAdriamycin Bax\u2193, Bcl-2\u2193, Beclin1\n\u2193,LC3B\u2193\nPI3K/AKT/m TOR myocardial protection\nYu et al. 2017\nChrysoeriol SH-SY5Y MPP + Bax\u2193, Bcl-2\u2193,Caspase-3\u2193 PI3K/AKT/m\nTOR\nanti-PD Limboonreung et\nal. 2020\nTricin RAW 264.7 LPS NO\u2193, TNF -\u03b1\u2193, IL-6\u2193, ERK\n\u2193, JNK\u2193, p38\u2193\nMAPK/NF\u03baB\nanti-inflammatory Jia et al. 2020\nLuteolin Caco-2 DSS OCLN\u2193, CLDN1\u2193, ZO1\u2193 STAT3 anti-inflammatory Li et al. 2021 Luteolin-4'-Oglucoside Hela cells DPPH, CCK8 anti-cancer and antioxidant Zeng et al. 2020 Acteoside phenylpropanoid\nglycosides\nBALB/c mice\nDNCB TNF-\u03b1\u2193, IL-6\u2193, IL-4\u2193,\nCD86\u2191, CD54\u2191\nNF-\u03baB anti-inflammatory Li et al. 2018\nSalidroside C57BL/6\nmice\nHigh-fat diet NOX2\u2193, Caspase 3\u2193 AMPK antioxidant Ju et al. 2017\nSalicylic acid other 11\u03b2-HSD1\u2013\ndeficient mice and C57Bl/6 mice\nHigh-fat diet 11\u03b2-HSD1 mRNA\u2193 11\u03b2-HSD1 hypoglycemic Nixon et al. 2012\nThe differential volatile components Cedrol terpenes CYP2B6\u2193, CYP3A4\u2193, CYP2C8\u2193,CYP2C9\u2193, CYP2C19\u2193\nCYP450 anti-inflammatory Jeong et al. 2014\n\u03b2-Ionone SGC-7901\ncells\nBax/Bcl-2\u2193, caspase-3\u2193 PI3K/AKT anti-tumor Ansari et al. 2016\nThe differential non-volatile components N-methylcytisine alkaloids Mice DSS TNF-\u03b1 \u2193, IL-6\u2193, IL-1\u03b2\u2193 NF-\u03baB anti-inflammatory Jiao et al. 2018 Sesamoside iridoids Rats CCl 4 against CCl4 \u2191 hepyrotection Usmanov et al. 2021\nForsythoside B phenylpropanoid\nglycosides\nRAW264.7 LPS TNF-\u03b1 \u2193, IL-\u21936, HMGB1\u2193,\nTREM-1\u2193, MPO\u2193\nNF-\u03baB anti-inflammatory Jiang et al. 2012\nMartynoside human\nherpes virus and Epstein-\nVirus survival rate \u2193 antiviral Tsai et al. 2020\nBarr virus\n*\u2193\uff1arestrain, reduce, decrease or downregulate; \u2191: activation, enhancement, increase or up-regulation"
        }
    ],
    "title": "Analysis of Phytochemical Components of Tibetan medicine Pedicularis Flava and Pedicularis muscicola by GC-MS and UHPLC-TOF-MS",
    "year": 2023
}